TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06750419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-TLX250 PET/CT
Description: 89Zr-TLX250, is a chimeric monoclonal antibody (INN name: girentuximab) with specificity for the CAIX (carbonic anhydrase 9) antigen, radiolabelled with the positron emitting radiometal zirconium- 89. Girentuximab has a CAS number of 916138-87-9. The chemical formula, without the 89Zr and the desferrioxamine, is C6460H1006N1718O2018S48 with a molecular mass of 146.5 kg/mol.~89Zr-TLX250 is formulated as a solution for IV administration in glass vials at the nominal dosage strength of 37 MBq (±10%) for single IV use. The mass dose of 89Zr-TLX250 to be used in this Phase 3 study will be 10 mg, labelled with 37 MBq (±10%) 89Zr per dose.
Study: NCT06749405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion algorithm based on Quantra®
Description: In addition to routine coagulation tests, a Quantra Qstat® analysis will be performed at baseline (before incision), at the end of native liver dissection, and after unclamping of the venous anastomoses. In the event of bleeding, additional Quantra Qstat® analyses may be conducted until bleeding control is achieved.~Transfusion and administration of blood-derived medications will be guided by the results of the Quantra Qstat® analyses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transfusion algorithm
Description: Transfusion and blood-derived medications will be guided by the results of routine coagulation tests.
Study: NCT05969665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Inspire 2
Description: A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre 3
Description: A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
Study: NCT06039852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Postural Management Night-time Intervention
Description: Essential elements and components of PMN-TI:~* Safe and comfortable position to enable sleep~* Positioning to enable UAD overnight~* Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~* Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~* Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk.
Study: NCT05576181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Oral Tablet
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: VP-16 is used for lymphodepletion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Hematological stem cell transplantation
Study: NCT05557773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Traditional Scoliosis Exercises
Description: Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Traditional Scoliosis Exercises
Description: Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Training
Description: Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
Study: NCT06262542

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: moxibustion and Chinese herbal medicine group
Description: Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion.
Study: NCT05364437

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fibres Mix
Description: The Fibre Mix, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
Study: NCT06262542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion and Chinese herbal medicine group
Description: Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion.
Study: NCT06224023

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of presepsin levels in ascites
Description: A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
Study: NCT06262659

Intervention type: OTHER
Intervention: Doppler Ultrasonography Assessment
Description: Preoperative data will be collected from the latest available data within the last month. Preoperative Doppler ultrasonography venous mapping for all patients will be performed by experienced Radiology Specialists.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated. AVF flow will be expressed in ml/min, and the vascular structure diameters and the distance of AVF from the skin will be indicated in mm. AVF depth will be calculated as the distance from the skin to the anterior wall of the AVF.
Study: NCT06004232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention
Description: The PRY-D curriculum is a mindfulness-based prenatal yoga intervention which utilizes techniques to build both embodiment and mindfulness, and has previously been shown to reduce depression in a small sample of pregnant women with clinical depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: TAU involves routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
Study: NCT05792020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Stimulation
Description: This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Stimulation
Description: This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Focused Ultrasound Stimulation
Description: This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
Study: NCT05503082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ubrogepant 50 MG [Ubrelvy]
Description: Ubrogepant 50 MG \[Ubrelvy\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ubrogepant 50 MG [Ubrelvy]
Description: Ubrogepant 50 MG \[Ubrelvy\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ubrogepant 100 MG [Ubrelvy]
Description: Ubrogepant 100 MG \[Ubrelvy\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ubrogepant 100 MG [Ubrelvy]
Description: Ubrogepant 100 MG \[Ubrelvy\]
Study: NCT05535530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PSIO
Description: new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
Study: NCT05197777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS associated to functional activities
Description: The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated functional task from an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. Elbow angles will be adjusted in a static position with a manual goniometer (60 degrees). The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes, undergoing repetitive movements. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat. The TCT - tDCS Stimulator Kit Research version, with 35 cm2 on M1 of the contralateral hemisphere for the rigth dominant hand. During the first 30 s of active tDCS, an initial period of ''ramping up'' is administered, in which the stimulator reaches the maximum programmed current (2 mA) to mimic cutaneous perceptions. A 2 mA intensity will be maintained during activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physiotherapy
Description: Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
Study: NCT04682509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
Study: NCT04737850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Thrombopoietin receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Thrombopoietin receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no active pharmaceutical ingredient
Study: NCT04910932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information on COVID-19
Description: Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website.

Intervention type: OTHER
Group type: OTHER
Intervention: Information on COVID-19
Description: Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website.
Study: NCT06553183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immersive virtual reality
Description: Exercise based on virtual reality video games. Immersive type will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physicaltherapy
Description: pneumatic compression, exercise and skin care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional physicaltherapy
Description: pneumatic compression, exercise and skin care
Study: NCT06423287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum LP-KFY04
Description: Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Take placebo in addition to the limited diet.
Description: Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
Study: NCT05120960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tepotinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tepotinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tepotinib plus osimertinib
Description: Given by PO
Study: NCT06449872

Intervention type: DEVICE
Group type: OTHER
Intervention: Obstetrics and Gynecology clinical applications for ultrasound diagnostic systems
Description: Up to 5 healthcare professionals trained and experienced in Obstetrics and Gynaecology ultrasound qualitatively assessed the diagnostic image quality of the Kosmos Diagnostic Ultrasound System against the benchmark Mindray M9 Ultrasound System.
Study: NCT04183179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy Family, Healthy Kids Program
Description: The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home
Study: NCT04162353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CD19 cCAR T cells
Description: BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
Study: NCT05319613

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual clinical visits with home lab kits and mailed HIV PrEP
Description: Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
Study: NCT06445881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Si Jun Zi Tang
Description: Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
Study: NCT04685070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296 (Almonertinib)
Description: Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
Study: NCT05198752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen mRNA Personalised Cancer SW1115C3
Description: Subcutaneous Injection
Study: NCT05539586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tecartherapy
Description: Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
Study: NCT05565742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC
Study: NCT05968976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake DBS
Description: 55 patients receive awake DBS (current standard procedure)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Asleep DBS
Description: 55 patients receive asleep DBS
Study: NCT05565742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05289934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Stimuli
Description: Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
Study: NCT05165472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadri-pulse theta burst stimulation
Description: High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quadri-pulse theta burst stimulation
Description: High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
Study: NCT06062693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart sensor egg training
Description: The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
Study: NCT06635863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 40mg
Description: Prednisone 40mg x 8weeks
Study: NCT06047457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dose A U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 U/I, IM on Day 1 and Week 12 with a total of 2 injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 U/I, IM on Day 1 and Week 12 with a total of 2 injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A
Description: Dose A U/I, IM on Week 24 and Week 36 with a total of 2 injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A
Description: Dose B U/I, IM on Week 24 and Week 36 with a total of 2 injections.
Study: NCT05029752

Intervention type: DEVICE
Group type: OTHER
Intervention: Vendys II Device
Description: Using the device
Study: NCT05931016

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-MWT
Description: Measurement of saturation and blood gas parameters under 6-MWT with different masks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiroergometry
Description: Measurement of saturation and blood gas parameters under spiroergometry with different masks.
Study: NCT06516939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bFGF
Description: Half-face randomized control
Study: NCT06448429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will have the usual diabetes care at the Grady Diabetes Clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will have the usual diabetes care at the Grady Diabetes Clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care model (CoCM)
Description: Collaborative care will include:~* Care with a behavioral health consultant (BHC)~* Measurement-based mental health care~* Systematic caseload reviews~* Medical management of depression~The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care.
Study: NCT04999267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INVEST
Description: The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.